Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2020 Earnings Conference Call - Final Transcript
Oct 27, 2020 • 05:00 pm ET
Ladies and gentlemen, thank you for standing by and welcome to the Ultragenyx's Third Quarter 2020 Financial Results and Corporate Update. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]
I would now like to hand the conference over to your host, Joshua Higa. Sir, please go ahead.
Good afternoon and welcome to the Ultragenyx financial results and corporate conference call for the third quarter 2020. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. I'm Joshua Higa, Director of Investor Relations. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Camille Bedrosian, Chief Medical Officer; Erik Harris, Chief Commercial Officer and Mardi Dier, our Chief Financial Officer, who joined the company a couple of weeks ago. Shalini Sharp, Executive Vice President for Finance is also on and will be available if needed for Q&A at the end of the scripted portion of this call.
I would like to remind investors that this call will include forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to the types of statements identified as forward-looking in our 2019 Annual Report on Form 10-K that was filed on February 14, 2020, our quarterly report on Form 10-Q that we filed today and our subsequent periodic reports filed with the SEC, which will all be available on our website in the Investor's section. These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those projected in any forward-looking statement. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, as well as risks related to our business, please see our periodic reports filed with the SEC.
I will now turn the call over to Emil.
Emil D. Kakkis
Good afternoon and thank you everyone for joining us on today's call. It's been a busy week, quarter and year for Ultragenyx. This matches the fundamental part of my philosophy for the company, which is a relentless focus on execution. I'm proud of how productive the company has been throughout the year across all facets of our diverse business. Regular [Phonetic] team and development teams have got to new approvals in two weeks in June. Commercial team and all the people supporting the products have rapidly and successfully launched those products to patients in need while still growing Crysvita and XLH and improving our annual guidance despite the global impact of COVID.
The clinical team are internally and jointly working with our partner, GeneTx, has delivered a series of positive updates on our gene therapy programs and